RE-SPECT-CVT-Study-data-published

Results from RE-SPECT CVT ® published - first trial of NOAC in cerebral venous thrombosisStudy published in JAMA Neurology investigated Pradaxa ® (dabigatran etexilate) in patients with cerebral venous and dural sinus thrombosis (CVT)First exploratory study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this populationThe study is part of Boehringer Ingelheim ’s commitment to advancing thrombosis care
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news